Trials / Recruiting
RecruitingNCT07192939
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-9813 capsules | HRS-9813 capsule; High dose |
| DRUG | HRS-9813 capsules | HRS-9813 capsule; Low dose |
| DRUG | HRS-9813 capsule mimetic | HRS-9813 capsule mimetic |
Timeline
- Start date
- 2025-10-29
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2025-09-25
- Last updated
- 2025-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07192939. Inclusion in this directory is not an endorsement.